Pharmaceutical Executive
IN OUR APRIL 2006 ISSUE, we will explore the results of a reader study—a" pulse check" as we think of it—on the topics of promotional programs, meeting spend, and compliance, cosponsored by Maritz Travel and Pharmaceutical Executive. The study asked industry leaders about their perceptions of their companies' physician meetings in terms of audience, format, and budget, as well as their views on compliance regulations.
IN OUR APRIL 2006 ISSUE, we will explore the results of a reader study—a" pulse check" as we think of it—on the topics of promotional programs, meeting spend, and compliance, cosponsored by Maritz Travel and Pharmaceutical Executive. The study asked industry leaders about their perceptions of their companies' physician meetings in terms of audience, format, and budget, as well as their views on compliance regulations. A total of 61 readers involved in compliance monitoring or management of promotional program budgets within the pharmaceutical industry responded.
Because of the small sample and non-scientific nature of the sampling, the results may not be representative of all Pharm Exec readers. Findings are more qualitative than quantitative, but they help to tell a story even without providing significant statistics. They begin to provide a picture of what your fellow industry executives believe.
Some Highlights Include:
In-person meetings and one-on-one sales calls are the most commonly used meeting formats. Respondents reported that these meeting formats are most effective for conveying product information and gaining strong physician participation.
Many respondents feel that their company is doing only an average job of reaching the right audience and getting a good turnout for their promotional meetings, so there is still much room for improvement.
In general, study respondents feel that pharma companies have taken recent changes in compliance regulations very seriously.
• Two-thirds of respondents agree that the pharma industry is strictly following compliance regulations.
• Respondents report having dedicated compliance departments and legal departments to handle issues related to compliance requests.
On average, companies received 24 compliance requests during the past year; three out of five came from a state, and the rest from federal agencies.
Stay tuned for more info in the April 2006 issue of Pharm Exec.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
To Tackle the Plastic Waste Crisis in Pharma, Here’s Where to Start
October 30th 2024By demonstrating big advancements in recycling, pharma companies will be much more likely to attract shareholders and other investors, giving themselves a leg up in the competition to lead the biopharmaceutical industry well into the future.